Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Total Current Liabilities data on file, last reported at $30.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 5.23% year-over-year to $30.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.3 million (up 5.23% YoY), and the FY2025 full-year result was $33.5 million, up 10.63% from the prior year.
• Total Current Liabilities eased to $30.3 million in Q1 2026, from $33.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $36.3 million in Q3 2025 to a low of $14.3 million in Q1 2024.
• A 5-year average of $23.0 million and a median of $21.7 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities plunged 35.5% in 2023 and surged 108.42% in 2024, its largest moves.
• Tracing SLDB's Total Current Liabilities over 5 years: stood at $22.5 million in 2022, then sank by 35.5% to $14.5 million in 2023, then surged by 108.42% to $30.3 million in 2024, then gained by 10.63% to $33.5 million in 2025, then fell by 9.53% to $30.3 million in 2026.
• Business Quant data shows SLDB's Total Current Liabilities at $30.3 million in Q1 2026, $33.5 million in Q4 2025, and $36.3 million in Q3 2025.